Concurrent 0 10 0 10 O
use 11 14 11 14 O
of 15 17 15 17 O
the 18 21 18 21 O
following 22 31 22 31 O
classes 32 39 32 39 O
of 40 42 40 42 O
inhibitors 43 53 43 53 O
of 54 56 54 56 O
CYP3A4 57 63 57 63 B-treatment
: 63 64 63 64 O
azole 65 70 65 70 B-treatment
antifungals 71 82 71 82 I-treatment
, 82 83 82 83 O
macrolide 84 93 84 93 B-treatment
antibiotics 94 105 94 105 I-treatment
, 105 106 105 106 O
protease 107 115 107 115 B-treatment
inhibitors 116 126 116 126 I-treatment

Considered 0 10 127 137 O
a 11 12 138 139 O
poor 13 17 140 144 O
medical 18 25 145 152 O
risk 26 30 153 157 O
due 31 34 158 161 O
to 35 37 162 164 O
a 38 39 165 166 O
serious 40 47 167 174 O
, 47 48 174 175 O
uncontrolled 49 61 176 188 O
medical 62 69 189 196 B-chronic_disease
disorder 70 78 197 205 I-chronic_disease
, 78 79 205 206 O
non 80 83 207 210 B-chronic_disease
- 83 84 210 211 I-chronic_disease
malignant 84 93 211 220 I-chronic_disease
systemic 94 102 221 229 I-chronic_disease
disease 103 110 230 237 I-chronic_disease
or 111 113 238 240 O
active 114 120 241 247 O
, 120 121 247 248 O
uncontrolled 122 134 249 261 O
infection 135 144 262 271 B-chronic_disease

Ewing 0 5 272 277 B-cancer
's 5 7 277 279 I-cancer
sarcoma 8 15 280 287 I-cancer
must 16 20 288 292 O
have 21 25 293 297 O
progressed 26 36 298 308 O
following 37 46 309 318 O
at 47 49 319 321 O
least 50 55 322 327 O
one 56 59 328 331 O
standard 60 68 332 340 O
prior 69 74 341 346 O
chemotherapy 75 87 347 359 B-treatment
regimen 88 95 360 367 I-treatment

Histologically 0 14 368 382 O
confirmed 15 24 383 392 O
Ewing 25 30 393 398 B-cancer
's 30 32 398 400 I-cancer
sarcoma 33 40 401 408 I-cancer

Known 0 5 409 414 O
hypersensitivity 6 22 415 431 O
to 23 25 432 434 O
olaparib 26 34 435 443 B-allergy_name
or 35 37 444 446 O
any 38 41 447 450 O
of 42 44 451 453 O
the 45 48 454 457 O
excipients 49 59 458 468 O
of 60 62 469 471 O
the 63 66 472 475 O
product 67 74 476 483 O

Known 0 5 484 489 O
to 6 8 490 492 O
be 9 11 493 495 O
serologically 12 25 496 509 O
positive 26 34 510 518 O
for 35 38 519 522 O
HIV 39 42 523 526 B-chronic_disease
and 43 46 527 530 O
receiving 47 56 531 540 O
antiviral 57 66 541 550 B-treatment
therapy 67 74 551 558 I-treatment

Life 0 4 559 563 B-clinical_variable
expectancy 5 15 564 574 I-clinical_variable
of 16 18 575 577 O
at 19 21 578 580 O
least 22 27 581 586 O
16 28 30 587 589 B-lower_bound
weeks 31 36 590 595 I-lower_bound

Major 0 5 596 601 B-treatment
surgery 6 13 602 609 I-treatment
within 14 20 610 616 O
14 21 23 617 619 B-upper_bound
days 24 28 620 624 I-upper_bound
of 29 31 625 627 O
starting 32 40 628 636 O
study 41 46 637 642 O
treatment 47 56 643 652 B-treatment

Participation 0 13 653 666 O
in 14 16 667 669 O
another 17 24 670 677 O
clinical 25 33 678 686 O
study 34 39 687 692 O
with 40 44 693 697 O
an 45 47 698 700 O
investigational 48 63 701 716 O
product 64 71 717 724 O
during 72 78 725 731 O
the 79 82 732 735 O
21 83 85 736 738 B-upper_bound
days 86 90 739 743 I-upper_bound
prior 91 96 744 749 I-upper_bound
to 97 99 750 752 O
first 100 105 753 758 O
dose 106 110 759 763 O
of 111 113 764 766 O
olaparib 114 122 767 775 B-treatment
and 123 126 776 779 O
temozolomide 127 139 780 792 B-treatment

Persistent 0 10 793 803 O
clinically 11 21 804 814 O
significant 22 33 815 826 O
toxicities 34 44 827 837 O
caused 45 51 838 844 O
by 52 54 845 847 O
previous 55 63 848 856 O
cancer 64 70 857 863 B-treatment
therapy 71 78 864 871 I-treatment

Pregnant 0 8 872 880 B-pregnancy

Previously 0 10 881 891 O
documented 11 21 892 902 O
diagnosis 22 31 903 912 O
of 32 34 913 915 O
myelodysplastic 35 50 916 931 B-cancer
syndrome 51 59 932 940 I-cancer
( 60 61 941 942 O
or 61 63 942 944 O
any 64 67 945 948 O
dysplastic 68 78 949 959 O
leukocyte 79 88 960 969 O
morphology 89 99 970 980 O
suggestive 100 110 981 991 O
of 111 113 992 994 O
MDS 114 117 995 998 B-cancer
) 117 118 998 999 O
or 119 121 1000 1002 O
acute 122 127 1003 1008 B-cancer
myeloid 128 135 1009 1016 I-cancer
leukemia 136 144 1017 1025 I-cancer

Prior 0 5 1026 1031 O
approval 6 14 1032 1040 O
from 15 19 1041 1045 O
insurance 20 29 1046 1055 O
company 30 37 1056 1063 O
to 38 40 1064 1066 O
obtain 41 47 1067 1073 O
oral 48 52 1074 1078 O
temozolomide 53 65 1079 1091 B-treatment
for 66 69 1092 1095 O
the 70 73 1096 1099 O
duration 74 82 1100 1108 O
of 83 85 1109 1111 O
the 86 89 1112 1115 O
study 90 95 1116 1121 O

Receiving 0 9 1122 1131 O
any 10 13 1132 1135 O
systemic 14 22 1136 1144 B-treatment
chemotherapy 23 35 1145 1157 I-treatment
, 35 36 1157 1158 O
radiotherapy 37 49 1159 1171 B-treatment
( 50 51 1172 1173 O
except 51 57 1173 1179 O
for 58 61 1180 1183 O
palliative 62 72 1184 1194 O
reasons 73 80 1195 1202 O
) 80 81 1202 1203 O
, 81 82 1203 1204 O
within 83 89 1205 1211 O
2 90 91 1212 1213 B-upper_bound
weeks 92 97 1214 1219 I-upper_bound
from 98 102 1220 1224 O
the 103 106 1225 1228 O
last 107 111 1229 1233 O
dose 112 116 1234 1238 O
prior 117 122 1239 1244 O
to 123 125 1245 1247 O
study 126 131 1248 1253 O
treatment 132 141 1254 1263 B-treatment

Subjects 0 8 1264 1272 O
with 9 13 1273 1277 O
known 14 19 1278 1283 O
active 20 26 1284 1290 B-chronic_disease
hepatitis 27 36 1291 1300 I-chronic_disease
B 37 38 1301 1302 I-chronic_disease
or 39 41 1303 1305 I-chronic_disease
C 42 43 1306 1307 I-chronic_disease

Symptomatic 0 11 1308 1319 O
uncontrolled 12 24 1320 1332 O
brain 25 30 1333 1338 B-cancer
metastases 31 41 1339 1349 I-cancer

Unable 0 6 1350 1356 O
to 7 9 1357 1359 O
swallow 10 17 1360 1367 O
orally 18 24 1368 1374 O
administered 25 37 1375 1387 O
medication 38 48 1388 1398 O
and 49 52 1399 1402 O
subjects 53 61 1403 1411 O
with 62 66 1412 1416 O
gastrointestinal 67 83 1417 1433 B-chronic_disease
disorders 84 93 1434 1443 I-chronic_disease
likely 94 100 1444 1450 O
to 101 103 1451 1453 O
interfere 104 113 1454 1463 O
with 114 118 1464 1468 O
absorption 119 129 1469 1479 O
of 130 132 1480 1482 O
study 133 138 1483 1488 O
medication 139 149 1489 1499 O

Uncontrolled 0 12 1500 1512 O
seizures 13 21 1513 1521 B-chronic_disease

